Lightlake Therapeutics Appoints Dr. David Kessler as Strategic Advisor

LONDON, Sept 24, 2012 /PRNewswire/ -- Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company" or "Lightlake"), an early stage biopharmaceutical company developing modern addiction treatments based on its expertise using opioid antagonists, announced today that it has appointed former US Food and Drug Administration Commissioner, Dr. David Kessler, as a strategic advisor.  

Dr. Kessler was the FDA Commissioner under presidents George H. W. Bush and Bill Clinton, where he directed a number of new programs including the regulation of marketing and sale of tobacco products to children and nutrition labeling for food. He is a graduate of Amherst College, the University of Chicago Law School, and Harvard Medical School, and has been the dean of the medical schools at Yale and the University of California, San Francisco. He currently serves on the board of various organizations including the National Center for Addiction and Substance Abuse at Columbia University as well as Drug Strategies, a non-profit research institute that promotes more effective drug abuse prevention, education and treatment.

"We are very pleased to add Dr. Kessler as a strategic advisor," said Dr. Roger Crystal, Chief Executive Officer of Lightlake. "With his wide range of experience in research, clinical medicine, education, administration, and law, Dr. Kessler will be a tremendous guide for us as we work to develop a range of treatments to common addictive disorders. Specifically, Dr. Kessler's major involvement with us will be to advise on the side-effects of addiction."

Dr. Kessler is also the author of "The End of Overeating: Taking Control of the Insatiable American Appetite," which examines how our bodies and minds are changed when we consume foods that contain sugar, fat, and salt. Last month, Lightlake reported positive final data from a Phase II study of the Company's proprietary opioid antagonist naloxone nasal spray treatment for patients with Binge Eating Disorder (BED), which is the most chronic and common of all eating disorders. Patients suffering from BED typically exhibit a lack of control eating foods typically high in sugar, fat or salt, are preoccupied with eating these types of foods, and are able to override the feeling of fullness. 

About Lightlake Therapeutics Inc.

Lightlake Therapeutics Inc. is a developing biopharmaceutical company aiming to build a platform of biopharmaceutical solutions to common addictions and related disorders. Currently, the Company is focused on providing a safe, effective and simple treatment for patients who are obese or overweight as a result of Binge Eating Disorder in addition to those patients suffering from Bulimia Nervosa. Lightlake recently acquired patents that will allow it to widen its product pipeline to address patients with addictions to opioid painkillers, methadone, cocaine and amphetamine. The Company anticipates launching a development program for each of these purposes in the future.

Safe Harbor

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward- looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

Contact:

Investor
Mr. Kevin Fickle
President
NUWA Group LLC
Tel: +1-925-330-8315
Email: [email protected]

Company
Dr. Roger Crystal
Lightlake Therapeutics Inc.
Tel: +44(0)-203-617-8739
Email: [email protected]

SOURCE Lightlake Therapeutics Inc.